Analytik Jena Gains Control of CyBio
Analytik Jena purchased the majority of Cybio at a 16% premium to the company’s stock price of €0.95 ($1.21) on February 19. According to the website Wer-Kauft-Wen.de, Analytic Jena plans to streamline CyBio’s manufacturing, sales and marketing, while keeping the structure of the company intact.
Jena, Germany 2/19/09 and 2/23/09—Analytik Jena AG has acquired a majority of CyBio AG by increasing its stake in the company from 5.48%, purchased on February 19, to 51.19% purchased on February 20 at the price of €1.10 ($1.41) per share as part of a voluntary offer to Cybio shareholders. The acquisition will add CyBio’s expertise in high-throughput screening (HTS) in the pharmaceutical market to Analytik Jena’s portfolio of DNA purification kits and PCR. CyBio’s revenues in the HTS market have been between €14 and €16 million ($22–$25 million), but last year the company posted a loss. According to Klaus Berka, CEO of Analytik Jena, the acquisition will also increase Analytik Jena’s distribution in areas where the company is not present, particularly in Asia and the US.
